Why The Oncology Institute, Inc.’s (TOI) Stock Is Up 5.24%
As of Thursday, July 30, The Oncology Institute, Inc.’s TOI share price has surged by 5.24%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: The Oncology Institute, Inc. (TOI)
The Oncology Institute, Inc. TOI
$4.86
-0.21
-4.14%
July 31, 2026 4:00:00 PM
EST
Volume: 1,004,854
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Commentary & Analysis
Why The Oncology Institute, Inc.’s (TOI) Stock Is Down 8.29%
As of Tuesday, July 28, The Oncology Institute, Inc.’s TOI share price has dipped by 8.29%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why The Oncology Institute, Inc.’s (TOI) Stock Is Up 5.02%
As of Monday, July 27, The Oncology Institute, Inc.’s TOI share price has surged by 5.02%, which has investors questioning if this is right time to sell.Michael Rose
Why The Oncology Institute, Inc.’s (TOI) Stock Is Down 5.49%
As of Wednesday, July 15, The Oncology Institute, Inc.’s TOI share price has dipped by 5.49%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why The Oncology Institute, Inc.’s (TOI) Stock Is Up 6.72%
As of Monday, July 06, The Oncology Institute, Inc.’s TOI share price has surged by 6.72%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | TOI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $485.9 | $1,742.7 | 37% |
|
| Shares Out (Mil) | 101.8 | 76.7 | 63% |
|
| Institutional Ownership | 78.2% | 89.7% | 48% |
|
| Float (Mil) | 86.7 | 49.4 | 59% |
|
| Beta | 0.36 | 0.82 | 20% |
|
| Avg Daily Volume (000s) | 1,391 | 521 | 76% |
|
| Price Change (52-week) |
31.7% | 78.7% | 70% |
|
| Growth | TOI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 21.8% | 11.0% | 83% |
|
| Net Income (5yr) | (33.5%) | (0.7%) | 12% |
|
| EPS (5yr) | (17.6%) | 3.1% | 15 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (37.0%) | (18.0%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TOI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $546 | $1,456 | 42% |
|
| Net Income (TTM) (Mil) | ($44) | $12 | 17% |
|
| EPS (TTM) | ($0.369) | $0.300 | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | $138 | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($10) | $8 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $98 | $316 | 44% |
|
| Enterprise Value (Q1) (Mil) | $476 | $2,170 | 34% |
|
| Valuation | TOI | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.85 | na |
|
| P/E | na | 26.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TOI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 15.1% | 27.8% | 14% |
|
| Net Margin | (8.0%) | 1.1% | 22% |
|
| ROA | (26.2%) | 1.8% | 18% |
|
| ROE | 775.9% | 7.1% | 100% |
|
| Liabilities to Assets | 109.7% | 59.9% | 95% |
|
| F-Score | 4 | 5 | 34% |
|
The Oncology Institute, Inc. did not pass any screens on 7/31/2026.
